期刊
MOLECULAR IMAGING
卷 17, 期 -, 页码 -出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1536012117745386
关键词
breast cancer; HER2-positive cancer; HER2 imaging; human epidermal growth factor 2; molecular imaging; PET/CT; SPECT/CT; receptor radionuclide therapy
资金
- NCATS NIH HHS [UL1 TR001863] Funding Source: Medline
- NCI NIH HHS [K99 CA201601, P30 CA013148] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [K99CA201601, P30CA013148] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presently, there are 2 standard diagnostic techniques to assess HER2 status in biopsies: immunohistochemistry and fluorescence in situ hybridization. While these techniques have played an important role in the treatment of patients with HER2-positive cancer, they both require invasive biopsies for analysis. Moreover, the expression of HER2 is heterogeneous in breast cancer and can change over the course of the disease. Thus, the degree of HER2 expression in the small sample size of biopsied tumors at the time of analysis may not represent the overall status of HER2 expression in the whole tumor and in between tumor foci in the metastatic setting as the disease progresses. Unlike biopsy, molecular imaging using probes against HER2 allows for a noninvasive, whole-body assessment of HER2 status in real time. This technique could potentially select patients who may benefit from HER2-directed therapy and offer alternative treatments to those who may not benefit. Several antibodies and small molecules against HER2 have been labeled with different radioisotopes for nuclear imaging and/or therapy. This review presents the most recent advances in HER2 targeting in nuclear medicine focusing on preclinical and clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据